OBJECTIVE: To observe therapeutic efficacy and safety of nedaplatin combined with paclitaxel in the treatment of advanced cervical cancer. METHODS： Totally 100 patients with advanced cervical cancer were randomly divided into observation group （50 cases） and control group （50 cases）. Both groups were given 6MV linear accelerator radiotherapy combined with intracavitary irradiation. Based on it， control group was additionally given Cisplatin injection 20 mg/m2，d1+Paclitaxel injection 35 mg/m2， d1 intravenously within 3 h. Observation group was additionally given Nedaplatin for injection 20 mg/m2，d1+Paclitaxel injection intravenously （same usage and dosage as control group）. A treatment course lasted for a week， and both groups received 6 courses of treatment. Short-term efficacies of 2 groups were observed， and the levels of vascular endothelial growth factor A （VEGF-A）， VEGF-C and VEGF-D， lymphatic microvessel density （LVD）， microvessel density （MVD）， toxic reaction were also observed before and after treatment. RESULTS: Total response rate （52.00％ vs. 32.00％） and disease control rate （86.00％ vs. 66.00％） of observation group were significantly higher than those of control group， with statistical significance（P＜0.05）. After treatment， the levels of VEGF-A， VEGF-C and VEGF-D， LVD， MVD in 2 groups were significantly lower than before treatment， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. The incidence of thrombocytopenia in observation group was significantly higher than control group， and the incidence of nausea and vomiting was significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS: Nedaplatin combined with paclitaxel can improve short-term efficacy of patients with advanced cervical cancer， reduce gastrointestinal reaction， VEGF level and inhibit the generation of tumor vessel， but great importance should be attached to platelet toxic reaction.